Filing Details
- Accession Number:
- 0001567619-23-001396
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-27 21:35:00
- Reporting Period:
- 2023-01-25
- Accepted Time:
- 2023-01-27 21:35:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557533 | Robert Jeffrey Ajer | C/O Biomarin Pharmaceutical Inc. 105 Digital Drive Novato CA 94949 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-25 | 49,000 | $67.81 | 90,088 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-25 | 44,825 | $115.65 | 45,263 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-01-25 | 4,175 | $116.15 | 41,088 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy Common Stock) | Disposition | 2023-01-25 | 2,200 | $0.00 | 2,200 | $67.81 |
| Common Stock | Stock Option (Right to buy Common Stock) | Disposition | 2023-01-25 | 46,800 | $0.00 | 46,800 | $67.81 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2013-11-15 | 2023-05-14 | No | 4 | M | Direct |
| 0 | 2013-11-15 | 2023-05-14 | No | 4 | M | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on February 28, 2022.
- The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- Reflects the number of options outstanding after the transactions from this specific stock option grant.
Billionaire Hedge Funds
